Adds 6 FDA Approved Products on a Medium Multiplexing Platform and Microbiology Know-how Enabling our Customers to Benefit from a New Sample-to-Result Solution Cost-Efficiently in Near Patient Care Setting; adds a Manufacturing and R&D site in Salt Lake City, UT, United States.

Singapore (June 21, 2018) – Vela Diagnostics signed an agreement to acquire Great Basin Scientific’s assets and will take over their site in Salt Lake City, UT, USA.

Great Basin Scientific has 6 FDA approved cartridge-based assays running on their own chip-based analyzer platform. The microbiology assays provide fast, multiple-pathogen diagnoses and are offered to the fastest growing point-of-care customers, including hospitals and near-patient care providers. The FDA approved products include: Stool Bacterial Pathogens; C. diff; Group B Strep; Shiga Toxin Direct; Staph ID/R Blood Culture; Bordetella Direct.

With Great Basin, Vela Diagnostics enters Microbiology market which adds to the current segments of the company – Virology, and Oncology.

“Great Basin’s technology is a strategic fit to the Vela portfolio as it covers medium multiplexing solutions and complements both Vela’s low multiplexing PCR and high multiplexing NGS platform. With the addition of the Great Basin’s technology, near-patient care customers will be able to benefit from this new microbiology offering in our existing geographies; and our presence in the US will be enhanced,” said Michael Tillmann the CEO of Vela Diagnostics.